133 related articles for article (PubMed ID: 31839880)
1.
Chui MH; Kjaer SK; Frederiksen K; Hannibal CG; Wang TL; Vang R; Shih IM
Oncotarget; 2019 Dec; 10(64):6870-6878. PubMed ID: 31839880
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
[TBL] [Abstract][Full Text] [Related]
3. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.
Ho CL; Kurman RJ; Dehari R; Wang TL; Shih IeM
Cancer Res; 2004 Oct; 64(19):6915-8. PubMed ID: 15466181
[TBL] [Abstract][Full Text] [Related]
4. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
[TBL] [Abstract][Full Text] [Related]
5. Interobserver Reproducibility in Assessing Eosinophilic Cells in Ovarian Serous Borderline Tumors to Predict BRAF Mutational Status.
Chui MH; Murali R; Soslow RA; Matrai C; Xing D; Vang R
Int J Gynecol Pathol; 2023 Sep; 42(5):472-481. PubMed ID: 36867514
[TBL] [Abstract][Full Text] [Related]
6. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion.
Prat J; De Nictolis M
Am J Surg Pathol; 2002 Sep; 26(9):1111-28. PubMed ID: 12218568
[TBL] [Abstract][Full Text] [Related]
7. BRAF
Turashvili G; Grisham RN; Chiang S; DeLair DF; Park KJ; Soslow RA; Murali R
Histopathology; 2018 Sep; 73(3):438-443. PubMed ID: 29770477
[TBL] [Abstract][Full Text] [Related]
8. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
[TBL] [Abstract][Full Text] [Related]
9. High Frequency of
Ishibashi T; Nakayama K; Razia S; Ishikawa M; Nakamura K; Yamashita H; Dey P; Iida K; Kurioka H; Nakayama S; Otsuki Y; Ishikawa N; Kyo S
Diagnostics (Basel); 2019 Dec; 10(1):. PubMed ID: 31892193
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.
McHenry A; Rottmann DA; Buza N; Hui P
Virchows Arch; 2023 Jul; 483(1):71-79. PubMed ID: 37219599
[TBL] [Abstract][Full Text] [Related]
11. Spectrum of
Chui MH; Chang JC; Zhang Y; Zehir A; Schram AM; Konner J; Drilon AE; Da Cruz Paula A; Weigelt B; Grisham RN
JCO Precis Oncol; 2021; 5():. PubMed ID: 34568720
[TBL] [Abstract][Full Text] [Related]
12. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
[TBL] [Abstract][Full Text] [Related]
13. v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior.
Verbruggen MB; Sieben NL; Roemen GM; Rockx DA; van Diest PJ; Verheijen RH; Dorsman JC
Int J Gynecol Cancer; 2009 Dec; 19(9):1560-3. PubMed ID: 19955937
[TBL] [Abstract][Full Text] [Related]
14. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
[TBL] [Abstract][Full Text] [Related]
15. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators.
Seidman JD; Kurman RJ
Hum Pathol; 2000 May; 31(5):539-57. PubMed ID: 10836293
[TBL] [Abstract][Full Text] [Related]
16. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
Sadlecki P; Walentowicz P; Bodnar M; Marszalek A; Grabiec M; Walentowicz-Sadlecka M
Tumour Biol; 2017 May; 39(5):1010428317706230. PubMed ID: 28488545
[TBL] [Abstract][Full Text] [Related]
17. Whole exome sequence analysis of serous borderline tumors of the ovary.
Boyd J; Luo B; Peri S; Wirchansky B; Hughes L; Forsythe C; Wu H
Gynecol Oncol; 2013 Sep; 130(3):560-4. PubMed ID: 23774303
[TBL] [Abstract][Full Text] [Related]
18. Germ line and somatic mutations of BRAF V599E in ovarian carcinoma.
Ueda M; Toji E; Noda S
Int J Gynecol Cancer; 2007; 17(4):794-7. PubMed ID: 17309670
[TBL] [Abstract][Full Text] [Related]
19. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases.
Seidman JD; Kurman RJ
Am J Surg Pathol; 1996 Nov; 20(11):1331-45. PubMed ID: 8898837
[TBL] [Abstract][Full Text] [Related]
20. Pathologic findings in eight cases of ovarian serous borderline tumors, three with foci of serous carcinoma, that preceded death or morbidity from invasive carcinoma.
Lee KR; Castrillon DH; Nucci MR
Int J Gynecol Pathol; 2001 Oct; 20(4):329-34. PubMed ID: 11603215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]